Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $4.95 USD
Change Today +0.10 / 2.06%
Volume 81.8K
ICAD On Other Exchanges
As of 8:10 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

icad inc (ICAD) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/3/14 - $11.63
52 Week Low
05/7/15 - $4.28
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ICAD INC (ICAD)

icad inc (ICAD) Related Bloomberg News

View More Bloomberg News

icad inc (ICAD) Related Businessweek News

No Related Businessweek News Found

icad inc (ICAD) Details

iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company provides electronic brachytherapy (eBX) products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, and skin cancer, as well as for the treatment of other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy. It also offers digital mammography computer-aided detection (CAD) products, such as advanced image analysis and workflow solutions in breast imaging, which include SecondLook digital CAD systems that detects and identifies suspicious masses and micro-calcifications; and PowerLook Advanced Mammography Platform, a computer server residing on a customer’s network that receives patient studies from the imaging modality, performs CAD analysis, and sends the CAD results to picture archiving and communication system and/or review workstations. In addition, the company’s digital mammography CAD products comprise magnetic resonance imaging applications, a tool to detect breast and prostate cancer; breast tomosynthesis systems; and advanced image analysis and workflow solutions in computed tomography (CT) colonography, including VeraLook that supports the detection of colonic polyps in conjunction with CT colonography. It serves hospitals, ambulatory care centers and free standing radiation oncology facilities, and other office-based uses. The company sells its products through sales organizations, as well as through various original equipment manufacturer partners, distributors, and resellers. It has a strategic partnership agreement with Invivo Corp. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was founded in 1984 and is headquartered in Nashua, New Hampshire.

141 Employees
Last Reported Date: 03/13/15
Founded in 1984

icad inc (ICAD) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $435.0K
President, Chief Financial Officer, Chief Ope...
Total Annual Compensation: $310.0K
Senior Vice President of Research & Developme...
Total Annual Compensation: $255.0K
Senior Vice President of Marketing & Strategy
Total Annual Compensation: $270.0K
Compensation as of Fiscal Year 2014.

icad inc (ICAD) Key Developments

iCAD Launches Digital Customer Training Platform to Support Professional Education in Use Of Xoft System for Treatment of Non-Melanoma Skin Cancer, Early-Stage Breast Cancer and Gynecological Cancers

iCAD, Inc. announced the launch of an enhanced eBx Institute including a new online learning and support platform for Xoft Electronic Brachytherapy (eBx) System users. eBx Institute will offer healthcare providers access to training modules and educational resources to support the treatment of non-melanoma skin cancer, early-stage breast cancer and gynecological cancers using the Xoft System. The web-based solution provides an array of on-demand, self-paced learning programs, including instructional courses and reference materials. eBx Institute will enable customers to: Self-enroll in training - Search for online course offerings - Manage course enrollments - View/print transcripts and training certificates upon course completion - Review supplemental training materials - Watch instructional procedure videos and online simulations. Xoft System users may consult the available information for a variety of different purposes including pre-requisite training, continuing education and post-ILT (instructor-led training) reference. The site also provides information to customers and addresses questions.

iCAD, Inc. Reports Unaudited Consolidated Financial Results for the First Quarter Ended March 31, 2015; Reiterates Earnings Guidance for Fiscal Year 2015

iCAD, Inc. reported unaudited consolidated financial results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenue of $13,220,000 against $8,520,000 a year ago. Income from operations was $443,000 against loss from operations of $460,000 a year ago. Loss before income tax expense was $1,778,000 against $137,000 a year ago. Net loss was $1,857,000 or $0.12 per basic and diluted share against $190,000 or $0.02 per basic and diluted share a year ago. Net cash used for operating activities was $183,000 against cash used for operating activities of $1,664,000 a year ago. Additions to property and equipment were $534,000 against $202,000 a year ago. Non GAAP adjusted EBITDA was $2,539,000 against $447,000 a year ago. Non GAAP adjusted net income was $259,000 against non GAAP adjusted net loss of $1,326,000 a year ago. Non GAAP adjusted net income per share was $0.02 against loss per share of $0.12 per share a year ago. The company is reiterating its fiscal year 2015 financial guidance. The company expects 2015 revenue to be in the range of $55 million to $59 million, representing growth of 25% to 34% compared to 2014. The company expects adjusted EBITDA margin in the 16% to 20% range.

iCAD, Inc. to Report Q1, 2015 Results on Apr 30, 2015

iCAD, Inc. announced that they will report Q1, 2015 results Pre-Market on Apr 30, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ICAD:US $4.95 USD +0.10

ICAD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Elekta AB kr60.60 SEK -0.70
Hologic Inc $35.05 USD +0.09
Merge Healthcare Inc $4.60 USD -0.01
View Industry Companies

Industry Analysis


Industry Average

Valuation ICAD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.6x
Price/Book 1.2x
Price/Cash Flow 49.8x
TEV/Sales 1.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ICAD INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at